ABP
Price
$1.04
Change
-$0.08 (-7.14%)
Updated
Jan 30, 04:59 PM (EDT)
Capitalization
58.03M
PHAT
Price
$6.14
Change
-$0.20 (-3.15%)
Updated
Jan 31, 11:39 AM (EDT)
Capitalization
447.87M
32 days until earnings call
Ad is loading...

ABP vs PHAT

Header iconABP vs PHAT Comparison
Open Charts ABP vs PHATBanner chart's image
Abpro Holdings
Price$1.04
Change-$0.08 (-7.14%)
Volume$4.4K
Capitalization58.03M
Phathom Pharmaceuticals
Price$6.14
Change-$0.20 (-3.15%)
Volume$800
Capitalization447.87M
ABP vs PHAT Comparison Chart
Loading...
ABP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABP vs. PHAT commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABP is a Hold and PHAT is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (ABP: $1.03 vs. PHAT: $6.34)
Brand notoriety: ABP and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABP: 6% vs. PHAT: 135%
Market capitalization -- ABP: $58.03M vs. PHAT: $447.87M
ABP [@Biotechnology] is valued at $58.03M. PHAT’s [@Biotechnology] market capitalization is $447.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABP’s FA Score shows that 0 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • ABP’s FA Score: 0 green, 5 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABP and PHAT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABP’s TA Score shows that 1 TA indicator(s) are bullish while PHAT’s TA Score has 3 bullish TA indicator(s).

  • ABP’s TA Score: 1 bullish, 2 bearish.
  • PHAT’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, PHAT is a better buy in the short-term than ABP.

Price Growth

ABP (@Biotechnology) experienced а -19.53% price change this week, while PHAT (@Biotechnology) price change was -11.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.80%. For the same industry, the average monthly price growth was +1.83%, and the average quarterly price growth was +5.53%.

Reported Earning Dates

PHAT is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-0.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($448M) has a higher market cap than ABP($58M). PHAT YTD gains are higher at: -21.921 vs. ABP (-42.458). ABP has higher annual earnings (EBITDA): -17.4M vs. PHAT (-272.21M). PHAT has more cash in the bank: 335M vs. ABP (13.6K). ABP has less debt than PHAT: ABP (160K) vs PHAT (176M). PHAT has higher revenues than ABP: PHAT (26.3M) vs ABP (122K).
ABPPHATABP / PHAT
Capitalization58M448M13%
EBITDA-17.4M-272.21M6%
Gain YTD-42.458-21.921194%
P/E RatioN/AN/A-
Revenue122K26.3M0%
Total Cash13.6K335M0%
Total Debt160K176M0%
TECHNICAL ANALYSIS
Technical Analysis
ABPPHAT
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 24 days ago
43%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 24 days ago
8%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 24 days ago
17%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 24 days ago
20%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 30 days ago
38%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Ad is loading...
ABP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EILVX26.48N/A
N/A
Eaton Vance Large-Cap Value I
JSCBX17.05N/A
N/A
JHancock Small Cap Value I
RRGCX6.97N/A
N/A
DWS RREEF Global Real Estate Secc C
LVPIX109.68N/A
N/A
ProFunds Large Cap Value Inv
TMPRX56.47N/A
N/A
Touchstone Mid Cap R6

ABP and

Correlation & Price change

A.I.dvisor tells us that ABP and CVM have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABP and CVM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABP
1D Price
Change %
ABP100%
-8.04%
CVM - ABP
32%
Poorly correlated
+3.66%
QSI - ABP
29%
Poorly correlated
-3.92%
NGNE - ABP
28%
Poorly correlated
+0.13%
PHAT - ABP
27%
Poorly correlated
-3.21%
TRAW - ABP
26%
Poorly correlated
-1.22%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with VERA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then VERA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
-3.21%
VERA - PHAT
43%
Loosely correlated
-1.19%
TNFA - PHAT
39%
Loosely correlated
-15.74%
ATRA - PHAT
36%
Loosely correlated
+4.94%
TCRX - PHAT
36%
Loosely correlated
+3.20%
AKRO - PHAT
32%
Poorly correlated
+2.52%
More